Grant: Catalyst Grant: Post Market Drug Safety and Effectiveness
Université de Montréal
$92,850.00
Use of short and long-acting beta2-agonists during pregnancy and the risk of congenital malformations
FY 2009-10
Summary
Asthma is one of the most prevalent chronic diseases complicating pregnancy, with a prevalence estimated to be between 4 and 8%. According to asthma guidelines, asthma should be treated as aggressively during pregnancy as at other times to maintain asthma under control and avoid adverse perinatal and maternal outcomes. Short-acting inhaled beta2-agonists (SABA) and long-acting inhaled beta2-agonists (LABA) are used to relief asthma symptoms: SABA being used as rescue medications when needed, while LABA are used in combination with inhaled corticosteroids as a controller therapy that should be used daily. Although it is recognized that asthma must be kept under control during pregnancy, physicians and asthmatic women are often reluctant to use asthma medications as recommended due to the fear of congenital malformations. This fear is certainly driven, at least in part, by the lack of solid safety data in pregnancy for asthma medications. The objective of this study is to evaluate whether or not the use of SABA and LABA during pregnancy is associated with an increased risk of birth defects. We will identify a group of asthmatic women who delivered in Québec between 1998 and 2008. We will evaluate the risk of all birth defects and major birth defects and compare these risks between women who used SABA and those who did not used these medications during the first trimester of pregnancy. We will also compare users and non-users of LABA. It is capital to evaluate the risk of birth defects associated with the use of SABA and LABA since these medications are routinely used during pregnancy. Knowing the risk, physicians will be able to recommend to safest therapy to treat asthma during pregnancy.
Department
Program
Catalyst Grant: Post Market Drug Safety and Effectiveness
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
192700
Name
Blais Lucie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Projecttitle
Use of short and long-acting beta2-agonists during pregnancy and the risk of congenital malformations
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$92,850
Cihrequipment2
$5,000
Programname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Keyworddelim
Administrative Databses; Asthma; Congenital Malformations; Pharmacoepidemiology; Pregnancy; Short And Long-Acting Beta2-Agonists
Abstract
Asthma is one of the most prevalent chronic diseases complicating pregnancy, with a prevalence estimated to be between 4 and 8%. According to asthma guidelines, asthma should be treated as aggressively during pregnancy as at other times to maintain asthma under control and avoid adverse perinatal and maternal outcomes. Short-acting inhaled beta2-agonists (SABA) and long-acting inhaled beta2-agonists (LABA) are used to relief asthma symptoms: SABA being used as rescue medications when needed, while LABA are used in combination with inhaled corticosteroids as a controller therapy that should be used daily. Although it is recognized that asthma must be kept under control during pregnancy, physicians and asthmatic women are often reluctant to use asthma medications as recommended due to the fear of congenital malformations. This fear is certainly driven, at least in part, by the lack of solid safety data in pregnancy for asthma medications. The objective of this study is to evaluate whether or not the use of SABA and LABA during pregnancy is associated with an increased risk of birth defects. We will identify a group of asthmatic women who delivered in Québec between 1998 and 2008. We will evaluate the risk of all birth defects and major birth defects and compare these risks between women who used SABA and those who did not used these medications during the first trimester of pregnancy. We will also compare users and non-users of LABA. It is capital to evaluate the risk of birth defects associated with the use of SABA and LABA since these medications are routinely used during pregnancy. Knowing the risk, physicians will be able to recommend to safest therapy to treat asthma during pregnancy.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Blais, Lucie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $92,850~ $5,000~